Welcome to Volume 13, Issue #10 (DECEMBER 2014) of Pharma Marketing News.
This article is a review of FDA's proposed study titled 'Spousal Influence on Consumer Understanding of and Response to Direct-To-Consumer Prescription Drug Advertisements' (FDA-2014-N-1819)
This article summarizes the comments from a LinkedIn debate and #mHealthPharma TweetChat and condenses the learnings into one simple formula for creating quality pharma mHealth apps.
A growing number of doctors prefer digital communications and the pharmaceutical industry is currently in the process of moving its sales force to a smaller structure that is more directly aligned with this new reality. One aspect of that change is the deployment of
Patient Activists Demand Higher Quality Mobile Health Apps: Pharma Must Listen, Respond, and Optimize!
Sooner or later Congress, perhaps urged on by patient advocates or some mhealth app adverse event, may investigate the mobile health app industry -- including the drug industry -- to see if further oversight, not just FDA regulations, is required. Before that happens and to ensure that mobile health apps developed by pharma are of the highest quality, the industry should differentiate itself from "wild west" developers by being pro-active in developing and abiding by a set of 'Guiding Principles for Mobile Health Apps.'
Welcome to Volume 13, Issue #4 (April 2014) of Pharma Marketing News.
Welcome to Volume 13, Issue #2 (February 2014) of Pharma Marketing News.
This article summarized the industry's response to the second FDA social media guidance document regarding correcting and/or responding to misinformation related to a firm's own FDA-approved products when that information is created or disseminated by independent third parties on the Internet or through social media.
These days, patient storytelling is all the rage. More often than not, however, patient stories told by pharma marketers are not 'providing truth' in the sense that they are real patient stories.
This article summarizes some of the main points made by PhRMA, Washington Legal Foundation (WLF), BIO, Medical Information Working Group (MIWG), Patient, Consumer, and Public Health Coalition, and several pharmaceutical companies, regarding FDA's Draft Guidance on using Internet and social media platforms with character space limitations.